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Abstract
The development of neuropathic syndromes is an important, dose limiting side effect of anticancer agents like platinum
derivates, taxanes and vinca alkaloids. The causes of neurotoxicity are still unclear but the impairment of the oxidative
equilibrium is strictly related to pain. Two intracellular organelles, mitochondria and peroxisomes cooperate to the
maintaining of the redox cellular state. Whereas a relationship between chemotherapy-dependent mitochondrial alteration
and neuropathy has been established, the role of peroxisome is poor explored. In order to study the mechanisms of
oxaliplatin-induced neurotoxicity, peroxisomal involvement was evaluated in vitro and in vivo. In primary rat astrocyte cell
culture, oxaliplatin (10 mM for 48 h or 1 mM for 5 days) increased the number of peroxisomes, nevertheless expression and
functionality of catalase, the most important antioxidant defense enzyme in mammalian peroxisomes, were significantly
reduced. Five day incubation with the selective Peroxisome Proliferator Activated Receptor-c (PPAR-c) antagonist G3335
(30 mM) induced a similar peroxisomal impairment suggesting a relationship between PPARc signaling and oxaliplatin
neurotoxicity. The PPARc agonist rosiglitazone (10 mM) reduced the harmful effects induced both by G3335 and oxaliplatin.
In vivo, in a rat model of oxaliplatin induced neuropathy, a repeated treatment with rosiglitazone (3 and 10 mg kg21 per os)
significantly reduced neuropathic pain evoked by noxious (Paw pressure test) and non-noxious (Cold plate test) stimuli. The
behavioral effect paralleled with the prevention of catalase impairment induced by oxaliplatin in dorsal root ganglia. In the
spinal cord, catalase protection was showed by the lower rosiglitazone dosage without effect on the astrocyte density
increase induced by oxaliplatin. Rosiglitazone did not alter the oxaliplatin-induced mortality of the human colon cancer cell
line HT-29. These results highlight the role of peroxisomes in oxaliplatin-dependent nervous damage and suggest PPARc
stimulation as a candidate to counteract oxaliplatin neurotoxicity.
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Introduction
Oxaliplatin is a chemotherapeutic compound widely used for
treating colorectal cancer [1]. The development of sensory
neuropathy is the most important, dose-limiting side effect.
Platinum-induced peripheral neuropathy is characterized by distal
paresthesias and mild muscle contractions for at least 80% of
oncologic patients after few hours to days from the first oxaliplatin
infusion [2,3]. Moreover, oxaliplatin repeated treatment induces
severe peripheral neuropathy that can affect approximately 50%
of the patients receiving cumulative doses higher than 1000 mg/
m2 [4,5]. Anti-hyperalgesic compounds currently used to treat
chemotherapy-induced pain, like antiepileptics or antidepressant,
are weakly effective [6]. The therapeutic failure reflects the lack of
knowledge about the molecular bases of neuropathies. In a rat
model of oxaliplatin-induced neuropathy we previously identified
oxidative stress as a main biomolecular dysfunction showing a
relationship between oxidative damage of the nervous system and
pain [7]. The ‘‘oxidative hypothesis’’ was confirmed in primary
cultures of astrocytes [8], a glial cell type activated in vivo by
oxaliplatin treatment [9]. Since oxaliplatin does not possess direct
oxidative properties [8], redox unbalance seems due to a cell-
mediated effect able to alter the oxidative machinery.
After oxaliplatin treatment, mitochondria are modified in
morphology and impaired in function [10]. Less inquired is the
role of the other intracellular organelle strongly implied in redox
processes: the peroxisome. Peroxisomes are the last among the
subcellular organelles to be identified [11]. The discovery of the
co-localization of catalase with H2O2-generating oxidases in
peroxisomes was the first indication of their involvement in the
metabolism of oxygen metabolites [11]. The high peroxisomal
consumption of O2, the demonstration of the production of H2O2,
O2
2, ?OH, and more recently of ?NO [11–14], as well as the
discovery of several ROS metabolizing enzymes in peroxisomes
has supported the notion that these ubiquitous organelles play a
key role in both the production and scavenging of ROS in the cell
[15]. In the nervous system, the functional relevance of these
organelles is dramatically highlighted by peroxisomal disorders.
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Severe demyelination, axonal degeneration and neuroinflamma-
tion are induced by genetic deficit of peroxisome [16–19].
Moreover, peroxisomes were recently involved in the development
and progression of specific degenerative diseases [18,20–22].
In mouse liver was originally cloned a nuclear receptor
subfamily of ligand-activated transcription factors, the Peroxisome
Proliferator-Activated Receptors (PPARs) [23]. PPARs may
activate genes with a PPAR response element (PPRE) in their
promoter regions [24]. Girnun et al. [25] highlighted that PPARc
stimulation increases the expression and activity of catalase, a
heme-containing peroxisomal enzyme that breaks down hydrogen
peroxide to water and oxygen [26,27]. Recently, agonists of the c
subtype of PPARs received considerable attention as potential
therapeutic agents for a wide range of neurological diseases,
including neurodegenerative diseases, traumatic injuries, stroke
and demyelinating diseases [28–38].
Aimed to characterize the oxaliplatin neurotoxicity, we studied
the peroxisome-related signal in vitro, in astrocyte cell culture, and
in vivo in a rat model. Peroxisome stimulation by the PPARc
agonist rosiglitazone was analyzed to individuate new possible
pharmacological approaches to control oxaliplatin-induced neu-
ropathy.
Materials and Methods
Astrocyte cultures
Primary cultures of astrocytes were obtained according to the
method described by McCarthy and de Vellis [39]. Briefly, the
cerebral cortex of newborn (P1–P3) Sprague–Dawley rats (Harlan,
Italy) was dissociated in Hanks’ balanced salt solution containing
0.5% trypsin/EDTA and 1% DNase (Sigma-Aldrich, Milan, Italy)
for 30 min at 37uC. The suspension was mechanically homoge-
nized and filtered. Cells were plated in high-glucose Dulbecco’s
Modified Eagle’s Medium (DMEM) with 10% fetal bovine serum
(FBS, Gibco, Invitrogen, Milan, Italy). Confluent primary glial
cultures were used to isolate astrocytes, removing microglia and
oligodendrocytes by shaking. The purity of astrocyte cultures was
determined immunocytochemically by staining for GFAP (Dako,
Glostrup, Denmark). Cells were fixed in 4% paraformaldehyde,
then incubated with the antibody (1:200), and visualized using
Alexa Fluor-conjugated secondary antibody (Life Technologies,
Figure 1. Catalase immunostaining in primary astrocytes. Cells (5?104 cells/well) were incubated for 5 days with 10 mM rosiglitazone (B), 1 mM
oxaliplatin (C), 1 mM oxaliplatin+10 mM rosiglitazone (D), 30 mM G3335 (E), negative control (F) in comparison to control condition (A). Representative
images are shown in the left panel. Scale bar 50 mm. The measurements of the number of peroxisomes/mm2 and the catalase optical density per
number of peroxisomes are shown in the upper and lower graphs, respectively. *P,0.01 vs control; ‘P,0.01 vs 1 mM oxaliplatin.
doi:10.1371/journal.pone.0102758.g001
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Monza, Italy). Nuclei were stained with 4,6-diamidino-2-pheny-
lindole dihydrochloride. 90% of cells in astrocyte cultures were
GFAP-positive. Experiments were performed 21 days after cell
isolation. Formal approval to conduct the experiments described
was obtained from the Animal Subjects Review Board of the
University of Florence. The ethics policy of the University of
Florence complies with the Guide for the Care and Use of
Laboratory Animals of the U.S. National Institutes of Health (NIH
Publication No. 85-23, revised 1996; University of Florence
Assurance No. A5278-01).
The human colon cancer cell line HT-29 was obtained from
American Type Culture Collection (Rockville, MD). HT-29 were
cultured in DMEM high glucose with 20% FBS in 5% CO2
atmosphere at 37uC. Media contained 2 mM L-glutamine, 1%
essential aminoacid mix, 100 IU ml21 penicillin and 100 mg ml21
streptomycin (Sigma, Milan, Italy).
Cell treatments
On day 21, astrocytes were plated in 12-wells cell culture
(2?105/well; Corning, Tewksbury MA, USA), or on polylysine-
coated slides (5?104/well) and experiments were performed after
48 h. Cells were treated with 10-and 1 mM oxaliplatin (Sequoia
Research Products, Pangbourne, UK) for 2 or 5 days respectively.
Rosiglitazone (10 mM; Sequoia Research Products, Pangbourne,
UK) and 30 mM G3335 (BioVision Incorporated, Milpitas, CA,
USA) were used in the presence or absence of oxaliplatin for 2 or 5
days. The chosen concentrations are in accord with previous
published data [8,40,41] and, as regards oxaliplatin, with
plasmatic concentration of treated rats.
HT-29 cells were plated in 96-wells cell culture (1?104/well)
and, 48 h after, treated as described above.
Cell viability assay
HT-29 cell viability was evaluated by the reduction of 3-(4,5-
dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as
an index of mitochondrial compartment functionality. Cells were
plated into 96-well cell culture plates, and treated after 48 h.
Oxaliplatin, at various concentrations, was incubated in DMEM
in the presence of 10 mM rosiglitazone for 48 h and 5 days. After
extensive washing, 1 mg/ml MTT was added into each well and
incubated for 30 minutes at 37uC. After washing, the formazan
crystals were dissolved in 150 ml dimethyl sulfoxide. The
absorbance was measured at 550 nm. Experiments were per-
formed in quadruplicate on at least three different cell batches.
Animals
For all the experiments described below, male Sprague-Dawley
rats (Harlan, Varese, Italy) weighing approximately 200 to 250 g
Figure 2. Expression and activity of catalase in astrocyte cell culture. Astrocytes (5?105 cells/well) were treated with the PPARc antagonist
G3335 (30 mM) or with oxaliplatin (1 mM) in the absence or in the presence of the PPARc agonist rosiglitazone (10 mM). Expression and activity were
measured after 48 h- (A and B, respectively) or 5 day-treatment (C and D, respectively). GAPDH normalization was performed for each sample. Values
are expressed as the mean 6 S.E.M. percent of control of three experiments. Control condition was arbitrarily set as 100%. *P,0.05 vs control; ‘P,
0.05 vs 1 mM oxaliplatin.
doi:10.1371/journal.pone.0102758.g002
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at the beginning of the experimental procedure were used.
Animals were housed in CeSAL (Centro Stabulazione Animali da
Laboratorio, University of Florence) and used at least 1 week after
their arrival. Four rats were housed per cage (size 26641 cm);
animals were fed with standard laboratory diet and tap water ad
libitum, and kept at 2361uC with a 12 hour light/dark cycle, light
at 7 a.m. All animal manipulations were carried out according to
the European Community guidelines for animal care (DL 116/92,
application of the European Communities Council Directive of 24
November 1986 (86/609/EEC). The ethical policy of the
University of Florence complies with the Guide for the Care and
Use of Laboratory Animals of the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996; University of Florence
assurance number: A5278-01). Formal approval to conduct the
experiments described was obtained from the Animal Subjects
Review Board of the University of Florence. All efforts were made
to minimize animal suffering and to reduce the number of animals
used.
Oxaliplatin model and pharmacological treatments
Oxaliplatin neuropathy was induced as described by Cavaletti
et al. [42]. Rats were treated with 2.4 mg kg21 oxaliplatin,
administered intraperitoneally (i.p.) for 5 consecutive days every
week for 3 weeks (15 i.p. injections). Oxaliplatin was dissolved in
5% glucose solution. Rosiglitazone at the doses of 3 and 10 mg
kg21 was suspended in 1% carboxymethylcellulose sodium salt
(CMC) and administered per os (p.o.) daily starting from the first
day of oxaliplatin administration up to day 20. Control animals
received an equivalent volume of vehicles: i.p. glucose or p.o.
CMC (vehicle). Behavioral, morphological and biochemical tests
were performed on day 21, 24 hours after last treatments. On day
21, organic platinum plasmatic levels evaluated by Inductively
Coupled Mass Spectrometry (ICP-MS) were 3.57360.271 mg/mL
(corresponding to oxaliplatin 7.27460.552 mg/mL or 18.3 mM).
Paw pressure test
The nociceptive threshold in the rat was determined with an
analgesimeter (Ugo Basile, Varese, Italy), according to the method
described by Leighton et al. [43]. Briefly, a constantly increasing
pressure was applied to a small area of the dorsal surface of the
hind paw using a blunt conical probe by a mechanical device.
Mechanical pressure was increased until vocalization or a
withdrawal reflex occurred while rats were lightly restrained.
Vocalization or withdrawal reflex thresholds were expressed in
grams. Rats scoring below 40 g or over 75 g during the test before
drug administration were rejected (25%). For analgesia measures,
mechanical pressure application was stopped at 120 g. Rats were
randomly assigned to each experimental group and individually
habituated to handling before testing.
Cold Plate Test
The animals were placed in a stainless box
(12 cm620 cm610 cm) with a cold plate as floor. The temper-
ature of the cold plate was kept constant at 4uC61uC. Pain-related
behaviors (i.e. lifting and licking of the hind paw) were observed
and the time (s) of the first sign was recorded. The cut-off time of
the latency of paw lifting or licking was set at 60 s.
Rota-Rod Test
The Rota-rod apparatus (Ugo Basile, Varese, Italy) consisted of
a base platform and a rotating rod with a diameter of 6 cm and a
non-slippery surface. The rod was placed at a height of 25 cm
from the base. The rod, 36 cm in length, was divided into 4 equal
sections by 5 disks. Thus, up to 4 rats were tested simultaneously
on the apparatus, with a rod-rotating speed of 10 r.p.m. The
integrity of motor coordination was assessed on the basis of the
time the animals kept their balance on the rotating rod up to a
maximum of 10 min (600 s). After a maximum of 6 falls from the
rod, the test was suspended and the time was recorded.
Tissue collection
On day 21, at the end of the behavioral test session, animals
were sacrificed by decapitation. L4-L5 dorsal root ganglia (DRG)
were dissected and frozen using liquid nitrogen. L4/L5 segments
of the spinal cord were exposed from the lumbovertebral column
via laminectomy and identified by tracing the dorsal roots from
their respective DRG. After dissection, this lumbar portion was
frozen using liquid nitrogen or fixed by immersion in 4% neutral
buffered formalin. Blood was collected in heparin-treated tubes
and plasma fraction was isolated by centrifugation.
Catalase immunoreaction in astrocyte cell culture
Cytological specimens were fixed in 4% paraformaldehyde for
10 minutes and then washed in PBS. For immunolabeling, slides
were treated with 0.3% H2O2 (v/v) in water to quench
endogenous peroxidase and then pre- incubated for 15 minutes
in Ultra V Block (Thermo Scientific, Rancom Cheshire, UK).
Successively, the slides were incubated with rabbit polyclonal anti-
Catalase antiserum at final dilution of 1:100 (Novus Biological,
Littelton, CO, USA). Immuno-reaction was revealed by biotin-
conjugated goat anti-rabbit IgG to a final dilution of 1:200 (Dako,
Glostrup, Denmark) followed by incubation with Streptavidin
Peroxidase Complex (Thermo Scientific, Rancom Cheshire, UK).
The morphology, size and cellular localization allowed us to
identify the stained bodies as peroxisomes.
Negative controls were carried out by omitting the primary or
the secondary antibodies. Staining was performed in a single
session, to minimize artifactual differences in the staining.
Numerous (.10) photomicrographs of cells were randomly taken
using a digital photomicroscopy apparatus with a 406 objective.
Each microscopic field corresponds to a test area of 38,700 mm2.
On the digitized images peroxisomes were counted in every single
cell and cell area was also measured Measurements were carried
out using ImageJ 1.33 free-share image analysis software (ImageJ,
NIH, Bethesda, Maryland, USA). The results were expressed as
number of peroxisomes/mm2. On the digitized images, measure-
ments of optical density of catalase-immunostained peroxisomes
were carried out after determining the appropriate threshold to
include only immune-reactive peroxisomes. The results were
expressed as mean of optical density/number of peroxisomes.
After determination of number and optical density of peroxisomes,
Figure 3. Pain threshold measurements. A) Noxious stimulus, Paw-pressure test. Rats were daily intraperitoneally treated with 2.4 mg kg21
oxaliplatin (dissolved in 5% glucose). Rosiglitazone (3 and 10 mg kg21, suspended in CMC) was per os daily administered starting from the first day of
oxaliplatin administration. B) Non-noxious stimulus, Cold plate test. The response to a thermal stimulus was evaluated by cold plate test measuring
the latency (seconds) to pain-related behaviors (lifting or licking of the paw). Control animals were treated with vehicles. Behavioral measures were
performed on day 7, 14 and 21, 24 h after the last treatment. Each value represents the mean of 10 rats per group, performed in 2 different
experimental set. *P,0.01 vs vehicle + vehicle (control); ‘P,0.01 vs oxaliplatin + vehicle.
doi:10.1371/journal.pone.0102758.g003
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the slides were counterstained with hematoxylin to highlight the
nuclei.
Catalase activity
Enzymatic activity was measured both in astrocyte culture and
in nervous tissue. After incubation, cells were washed once with
PBS and scraped with PBS on ice. Cells were then collected,
subjected to a freeze–thaw cycle and centrifuged (13,0006g for
10 min at 4uC). DRG and spinal cord were homogenated in PBS.
The suspension was sonicated on ice using three 10 s bursts at high
intensity with a 10 s cooling period between each burst and then
centrifuged (13,0006g for 15 minutes at 4uC). Catalase activity
was measured in the supernatant by Amplex Red Catalase Assay
Kit (Invitrogen, Monza, Italy) following the manufacturer’s
instructions.
Protein concentration was quantified by bicinchoninic acid
assay (Sigma–Aldrich, Milan, Italy). Catalase activity for each
sample was normalized to protein concentration. Control condi-
tions in the absence of treatment were set as 100%.
Lipid peroxidation
Thiobarbituric acid reactive substances (TBARS) were quanti-
fied in spinal cord tissue homogenate as described previously [7].
Tissue homogenate (1.5 mg) was added to 4 mL reaction mixture
consisting of 36 mM thiobarbituric acid (Sigma-Aldrich, Milan,
Italy) solubilized in 10% CH3COOH, 0.2% SDS, pH was
adjusted to 4.0 with NaOH. The mixture was heated for
60 minutes at 100uC and the reaction was stopped by placing
the vials in ice bath for 10 minutes. After centrifugation (at 1.600 g
at 4uC for 10 minutes) the absorbance of the supernatant was
measured at 532 nm (Perkin-Elmer spectrometer, Monza, Italy)
and TBARS were quantified in mmoles/milligram of total protein
using 1,1,3,3-tetramethoxypropane as standard. Protein homoge-
nate concentration was measured by bicinchoninc acid (BCA;
Sigma-Aldrich, Milan, Italy) assay.
Western blotting analysis
After incubation, astrocyte cell cultures were washed once with
PBS and scraped on ice with lysis buffer containing 50 mM Tris-
HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100,
Complete Protease Inhibitor (Roche, Milan, Italy). Cells were then
collected, subjected to a freeze–thaw cycle and centrifuged at
13,0006g for 10 min at 4uC. Nervous tissue (DRG and spinal
cord) from treated animals was homogenized in the lysis buffer
described before. The suspension was sonicated on ice using three
10 s bursts at high intensity with a 10 s cooling period between
each burst and then centrifuged (13,0006g for 15 minutes at 4uC).
Protein concentration was quantified by bicinchoninic acid assay.
Forty mg of each sample were resolved with 10% SDS-PAGE
before electrophoretic transfer onto nitrocellulose membranes
(Biorad, Milan, Italy). Membranes were blocked with 5% nonfat
dry milk in PBS containing 0.1% Tween 20 (PBST) and then
probed overnight at 4uC with primary antibody specific versus
catalase (1:1000; 60 kDa; Novus Biological, Littleton, CO, USA),
GAPDH (1:1000; 38 kDa; Cell Signaling, Boston, MA, USA).
Membranes were then incubated for 1 hour in PBST containing
the appropriate horseradish peroxidase-conjugated secondary
antibody (1:5000; Cell Signalling, USA). ECL (Enhanced chemi-
luminescence Pierce, Rockford, IL, USA) was used to visualize the
peroxidase-coated bands. Densitometric analysis was performed
using the ‘‘ImageJ’’ analysis software (ImageJ, NIH, Bethesda,
Maryland, USA) and results were normalized to GAPDH
immunoreactivity as internal control. Values are reported as
percentages in comparison to control which was arbitrarily fixed at
100%.
Carbonylated protein evaluation
Carbonylated proteins were evaluated in tissue homogenates as
described previously [7]. Twenty mg of each spinal cord sample
were denatured by 6% SDS and derivatized by 15-minute
incubation with 2,4 dinitrophenyl hydrazine (DNPH; Sigma-
Aldrich, Italy) at room temperature. Samples were separated on a
4–12% sodium dodecyl sulfate (SDS)-polyacrylamide gel by
electrophoresis and transferred onto nitrocellulose membranes
(Biorad, Italy). The membranes were incubated overnight with
primary antibody specific versus DNPH (1:5000; Sigma-Aldrich,
Milan, Italy). Afterwards the procedure described for Western
blotting analysis was followed. For each experiment the density of
all bands showed in a lane was reported as mean. b-actin was used
as loading control.
Figure 4. Motor coordination in oxaliplatin-treated rats. The integrity of the animals’ motor coordination was assessed using a rota-rod
apparatus. Rats were placed on a rotating rod (10 rpm) for a maximum of 10 minutes (600 seconds). The number of falls (A) and the time spent in the
balance (B) during 10 minutes were counted. Treatments (oxaliplatin 2.4 mg kg21 i.p. and rosiglitazone 3 and 10 mg kg21 p.o.) were performed daily.
Motor coordination was evaluated on day 21, 24 h after the last treatment. Each value represents the mean of 10 rats per group, performed in 2
different experimental set. *P,0.01 vs vehicle + vehicle (control); ‘P,0.05 vs oxaliplatin + vehicle.
doi:10.1371/journal.pone.0102758.g004
Table 3. Lipid peroxidation in spinal cord.
TBARS
(mmol/mg protein)
vehicle + vehicle 35.0567.25
oxaliplatin + vehicle 133.02623.45*
oxaliplatin + rosiglitazone 3 mg kg21 29.6867.12‘
oxaliplatin + rosiglitazone 10 mg kg21 39.27693.45‘
On day 21, the lumbar tract of the spinal cord was explanted for the analysis of lipid peroxidation. Data were expressed as mean 6 SEM of Thiobarbituric Acid Reactive
Substances (TBARS) levels (mmol/mg protein). Each value represents the mean of 10 rats per group, performed in 2 different experimental set. *P,0.01 vs vehicle +
vehicle (control); ‘P,0.05 vs oxaliplatin + vehicle.
doi:10.1371/journal.pone.0102758.t003
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Glial Fibrillary Acid Protein (GFAP) immuno reaction
Formalin-fixed cryostat sections (20 mm) were incubated for 1 h
in blocking solution (Bio-Optica; Milan, Italy) at room tempera-
ture; and were then incubated for 24 h at 4uC in PBST containing
rabbit primary antisera diluted 1:1000 and 5% normal donkey
serum. The primary antibody was directed against glial fibrillary
acidic protein (GFAP; 1:5000; Chemicon, Temecula, USA) for
astrocyte staining. After rinsing in PBST, sections were incubated
in donkey anti-rabbit IgG secondary antibody labeled with Alexa
Fluor 488 (1:1000, Invitrogen, Monza, Italy) at room temperature
for 1 h. Negative control sections (no exposure to the primary
antisera) were processed concurrently with the other sections for
all immunohistochemical studies. We obtained a single optical
density value for the dorsal horns by averaging the two sides in
each rat, and these values were compared to the homologous
average values from the vehicle-treated animals. Images were
acquired by a motorized Leica DM6000B microscope equipped
with a DFC350FX camera (Leica, Mannheim, Germany).
Microglia and astrocyte morphology was assessed by inspection
of at least three fields (40X 0.75NA objective) in the dorsal horn
and cerebral areas per section. Quantitative analysis of GFAP -
positive cells was performed by collecting at least three indepen-
dent fields through a 20X 0.5NA objective. GFAP-positive cells
were counted using the ‘‘cell counter’’ plugin of ImageJ. The
GFAP signal in immunostained sections was quantified using FIJI
software (distributed by ImageJ, NIH, Bethesda, Maryland, USA)
by automatic thresholding images with the aid of the ‘‘Moments’’
algorithm, which we found to provide the most consistent pattern
recognition across all acquired images. Area fraction (%) occupied
by the thresholded GFAP signal revealed a common trend
between GFAP expression and astrocyte cell number. Five spinal
cord sections were analyzed for each animal.
Determination of tissue platinum concentration
Plasma samples were pre-treated with nitric acid as described by
[44] with minor modifications. Platinum levels were measured by
Inductively Coupled Mass Spectrometry (ICP-MS) according to
[45] in the ‘‘Laboratorio di Microanalisi’’ of the University of
Florence.
Statistical analysis
Results are expressed as mean 6 SEM and analysis of variance
(ANOVA) was performed. A Bonferroni’s significant difference
procedure was used as post hoc comparison. All assessments were
made by researchers blinded to cell or rat treatments. Slides from
control and experimental groups were labeled with numbers so
that the person performing the image analysis was blinded as to
the experimental group. In addition all images were captured and
Figure 5. Expression and activity of catalase in the nervous tissue of oxaliplatin-treated animals. On day 21, dorsal root ganglia (DRG)
and spinal cord were analyzed to measure both expression and activity of catalase. Densitometric analysis and representative Western blot of catalase
expression in DRG (A) and spinal cord (C) are shown. GAPDH normalization was performed for each sample. Catalase enzymatic activity
measurements in DRG (B) and spinal cord (D). Values are expressed as the mean 6 S.E.M. percent of control of 10 rats per group, performed in 2
different experimental set. Each value represents the mean of *P,0.05 vs vehicle + vehicle; ‘P,0.05 vs oxaliplatin + vehicle.
doi:10.1371/journal.pone.0102758.g005
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Figure 6. Levels of carbonylated proteins in the spinal cord of oxaliplatin-treated rats. At 21th day, the lumbar tract of the spinal cord was
explanted and analyzed to measure protein oxidation. Densitometric analysis (top panel) and representative Western blot (lower panel) are shown. B-
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analyzed by an investigator other than the one who performed
measurements to avoid possible bias. Data were analyzed using the
‘‘Origin 8.1’’ software (OriginLab, Northampton, MA, USA).
Results
Primary rat astrocytes
In astrocyte cell culture, peroxisomes were highlighted as
catalase-positive organelles. After 5 day incubation, 1 mM
oxaliplatin increased the number of peroxisomes by 54%
(Figure 1). The PPARc agonist rosiglitazone (10 mM) fully
prevented the increase whereas 10 mM rosiglitazone per se
(without oxaliplatin) did not modify peroxisome number. On the
contrary the PPARc antagonist G3335 (30 mM) was able to
increase peroxisomes to the same extent of oxaliplatin (45%;
Figure 1). G3335 effect was rosiglitazone-inhibitable (data not
shown). The incubation for 48 h with 10 mM oxaliplatin induced
similar effects (data not shown). Aimed to investigate the
expression level of catalase in peroxisomes, we measured the ratio
between the optical density value of catalase immunostaining and
the number of peroxisomes. Oxaliplatin (1 mM, 5 day incubation)
reduced the ratio by about 60% in comparison to the control value
(Figure 1). G3335 (30 mM) decreased catalase expression similarly
to oxaliplatin while 10 mM rosiglitazone significantly prevented
alterations (Figure 1). After 48 h incubation, 10 mM oxaliplatin
and 30 mM G3335 reduced the ratio by 26% and 49% (data not
shown).
Similar alterations of catalase expression profile were measur-
able by Western blot. Protein level decreased from the control
value of 100% to 68.368.1% after 48 h incubation with 10 mM
oxaliplatin (Figure 2A) and to 79.465.4% after 5 day incubation
with 1 mM oxaliplatin (Figure 2C). Moreover, the chemothera-
peutic agent impaired the enzymatic activity of catalase. After
48 h, 10 mM oxaliplatin reduced catalase activity from 100%
(control) to 62.365.1% (Figure 2B); five day incubation with 1 mM
oxaliplatin reduced activity to 62.065.5% (Figure 2D). Effects
evoked by oxaliplatin in 5 day incubation were mimicked by the
PPAR-c antagonist G3335 (30 mM). Catalase expression de-
creased to 64.467.2% (Figure 2C) and activity up to 62.265.3%
(Figure 2D). The PPAR-c agonist rosiglitazone (10 mM) prevented
both oxaliplatin- (Figure 2D) and G3335-dependent (data not
shown) alterations. Neither G3335 nor rosiglitazone were effective
after 48 h of treatment. Aimed at evaluating the potential
interaction between rosiglitazone treatment and the therapeutic
property of oxaliplatin, we measured the viability of the human
colon cancer cell line HT-29. Tables 1 and 2 show the lack of
influence by the PPAR-c agonist on the concentration-dependent
(0.1–100 mM) oxaliplatin lethal effect after 48 h and 5 day
incubation.
Behavioural measurements
Seven days after the beginning of oxaliplatin treatment (2.4 mg
kg21 i.p., daily) pain sensitivity towards noxious stimulus (Paw
pressure test) was altered. The weight tolerated on the posterior
paw significantly decreased from the control value of 73.360.8 g
to 49.061.5 g (Figure 3A). Rosiglitazone, 3 and 10 mg kg21, per
os administered daily, limited hypersensitivity increasing the
tolerated weight (60.062.1 g and 61.962.3, respectively;
Figure 3A). The progression of oxaliplatin-dependent neuropathic
state on day 14 and 21 (Figure 3A) was reduced dose dependently
by rosiglitazone (Figure 3A). In Figure 3B the withdrawal
threshold to non-noxious thermal stimulus was shown. Cold plate
test highlighted a decreased pain threshold starting from the 2nd
week of oxaliplatin treatment (9.660.8 s, oxaliplatin + vehicle
group, in comparison to vehicle + vehicle group, 19.360.3 s). On
day 14 pain threshold was increased by 49% and 84% in 3 and
10 mg kg21 rosiglitazone-treated animals, respectively. Both
rosiglitazone dosages were effective on day 21 increasing pain
threshold by 39% and 49%, respectively (Figure 3B). On day 21,
motor coordination was evaluated by Rota rod test measuring the
walking time and the number of falls in 600 s. In comparison with
control rats (number of falls 1.360.3, time 600 s) oxaliplatin
treated animals fell down 5.660.4 times (Figure 4A) and
maintained the balance for 162.0638.5 seconds (Figure 4B) and.
Three mg kg21 rosiglitazone reduced the number of falls to
2.860.6 (Figure 4A) and improved the time of walking to
490645 seconds (Figure 4B). The higher dosage of rosiglitazone
was ineffective.
Ex vivo evaluation
Aimed to evaluate in vivo the relationship between oxaliplatin
neurotoxicity and peroxisome, catalase expression and activity
were measured in peripheral and central nervous tissue on day 21
of anticancer treatment. In DRG, catalase expression decreased
up to 72.9610.7% in comparison to the control value (10068.7%,
Figure 5A), the enzymatic activity was reduced up to 75.665.8%
(Figure 5B). Rosiglitazone (3 mg kg21 and 10 mg kg21) prevented
catalase impairment (Figure 5A and B). Figures 5C and 5D show
the oxaliplatin-induced decrease of catalase expression
(68.067.2%) and functionality (66.269.9%) in the spinal cord.
The lower dosage of rosiglitazone (3 mg kg21) only, was able to
prevent catalase alteration in spinal cord (Figure 5C and D).
Moreover, both the doses of rosiglitazone limited the oxidative
damage induced by oxaliplatin. As shown in Table 3, the lipid
peroxidation promoted by the anticancer agent (up to 4 times as
the basal value) was prevented by 3 and 10 mg kg21 rosiglitazone.
Protein oxidation, evaluated as increase of the expression level of
carbonylated protein was significantly prevented by rosiglitazone
(Figure 6). Aimed to better understand the role of astrocyte cells in
the modulation of neuropathic pain, we performed immunohis-
tochemical analysis of GFAP-positive cells in the dorsal horn of the
spinal cord (Figure 7). The oxaliplatin-dependent increase of cell
number (about 25% increase in oxaliplatin + vehicle as compared
to vehicle + vehicle), was prevented by 10 mg kg21 rosiglitazone
(Figure 7).
Discussion
Neuropathy is a dose limiting side effect of many anticancer
agents, including oxaliplatin. In the clinical practice, the common
human dosage of oxaliplatin is 85 mg/m2 and cumulative doses
higher than 1000 mg/m2 [4,5] causes chronic neuropathy in
approximately 50% of patients. The human plasmatic concentra-
tion of inorganic platinum after a single i.v. injection of 85 mg/m2
is on average about 3 mg/mL and only limited accumulation is
observed in plasma after repeated cycles (five consecutive cycles at
85 or 130 mg/m2 every 3 weeks) [46,47].
The model used for the present research is consistent with the
clinical practice. 2.4 mg kg21 oxaliplatin corresponds to the
common human dosage (considering the Km factor 37 for the
actin normalization was performed for each sample. Values are expressed as the mean 6 S.E.M. percent of control of 10 rats per group, performed in
2 different experimental set. Each value represents the mean of *P,0.05 vs vehicle + vehicle; ‘P,0.05 vs oxaliplatin + vehicle.
doi:10.1371/journal.pone.0102758.g006
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Figure 7. Glial profile in spinal cord scored with GFAP-positive cells in the dorsal horn of the lumbar tract. Transverse sections of spinal
cord imaged with 20X objective of A) vehicle + vehicle, B) oxaliplatin + vehicle, C) and D) oxaliplatin + rosiglitazone 3 and 10 mg kg21, respectively.
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conversion of animal doses to the Human Equivalent Dose
[48,49]). The daily repeated administration of 2.4 mg kg21
performed in the animal model allows to obtain a cumulative
dose of 36 mg kg21 corresponding to 1332 mg/m2. This dosage
mimics the clinical cumulative oxaliplatin dose causing chronic
neuropathy. Moreover, in our condition the inorganic platinum
plasmatic levels after 21 days of treatment is 3.57360.217 mg/mL
in line to human plasma concentration.
Among the debated biomolecular mechanisms of nervous
damage induced by platinum derivatives [50], we previously
indicated the oxidative stress as exploitable pathological target for
the treatment of chemotherapy-induced neuropathy. In our
model, a relationship between oxaliplatin-induced neuropathic
pain and oxidative damage was shown [7]. The cellular redox
balance is mainly regulated by two organelles, mitochondria and
peroxisomes, and the oxidative homeostasis is due to their
cooperation [51]. Mitochondrion was extensively studied and it
is considered a pivotal target of platinum neurotoxicity since
Zheng et al. [10] described an increase in the incidence of swollen
and vacuolated mitochondria in peripheral nerve axons in animals
treated with oxaliplatin. Moreover, we have recently confirmed
that oxaliplatin promotes a significant cytosolic release of
cytochrome C in astrocyte cell culture, indicating a mitochondrial
suffering [52]. On the contrary, the peroxisomal compartment was
poor analyzed and its relevance in cellular redox metabolism has
been underestimated for a long time [22]. Peroxisomes are single-
membrane bound organelles with a protein-rich matrix and play a
key role in both the production and scavenging of ROS in the cell
[15]. Catalase is the most important antioxidant defense enzyme
in mammalian peroxisomes breaking down hydrogen peroxide to
water and oxygen [26,53,54]. Catalase alterations are highlighted
in many neurodegenerative conditions correlate to oxidative
damage. Brain of aged patients showed a reduced catalase
functionality [55], similarly catalase activity was affected in a rat
model of Parkinson’s disease [56]. Catalase impairment was also
described in neuropathic conditions since decreased catalase
efficiency was described in sciatic nerve of rats affected by diabetic
neuropathy [57] as well as in brain regions of animals with delayed
neuropathy induced by organophosphate [58]. On the other hand,
the oxidative unbalance of these painful conditions has never been
associated with peroxisome alterations.
The present results highlight the relevance of peroxisomes in
oxaliplatin-dependent neurotoxicity. In astrocyte culture, glial cells
implied in the development and maintenance of chronic pain [59],
[60] and sensitive to the platinum drug toxicity [8], oxaliplatin
increases the number of peroxisomes. Peroxisomes are able to
respond to physiological changes in cellular environment adapting
their number, morphology, enzyme content and metabolic
functions [61]. In particular, alterations of peroxisome number
were described during carcinogenesis and liver cirrhosis, suggest-
ing proliferative mechanisms as well as peroxisome division [61].
In our condition, the increase in peroxisome number is insufficient
to provide the physiological level of catalase functionality. Both
activity and expression of this antioxidant enzyme are reduced in
astrocytes by oxaliplatin treatment. Astrocytes are generally less
susceptible to oxidative injury than neurons and provide for their
health and functionality [62,63]. The dysregulation of astrocyte
antioxidant machinery can influence neuron functionality and
evoke nervous circuit alterations. Accordingly, in the rat model of
oxaliplatin-induced neuropathy a similar alteration of catalase is
highlighted in DRGs and spinal cord. These data suggest an
impairment of peroxisome that may participate to oxaliplatin-
induced redox unbalance previously observed in astrocyte culture
as well as in the nervous tissue of neuropathic animals [7,8].
Oxaliplatin-induced alteration of catalase, in terms of activity
and expression, is comparable to that evoked by the pharmaco-
logical blockade of PPARc (by the selective and reversible PPARc
antagonist G3335 [41]). PPARs belong to a nuclear receptor
superfamily actively involved in immunoregulation. Membrane
lipid composition, cell proliferation, sensitivity to apoptosis, energy
homeostasis, and various inflammatory transcription factors are
regulated by the trans-repression capabilities of these receptors
[64]. The c subtype of PPARs is expressed both in neurons [65]
and glia cells [66] and PPARc stimulation protects neuronal and
axonal damage induced by oxidative stimuli [67]. This property
has been associated with a concomitant increase in the enzymatic
activity of catalase [67] accordingly to the evidence of a direct
modulation of this enzyme by PPARc [25]. The similarity of
oxaliplatin- and G3335-mediated effects on astrocyte catalase and
peroxisome number suggests a common dysregulation of these
organelles. Since oxaliplatin impairs catalase in 48 h whereas
G3335 needs 5 days, we can hypothesize a direct effect of
oxaliplatin on the peroxisome machinery. On the other hand, 5
days incubation with the selective PPARc agonist rosiglitazone,
reduces the enzymatic failure promoted by both oxaliplatin and
G3335 and normalizes the peroxisome number. Accordingly, the
repeated administration of rosiglitazone improves catalase effi-
ciency in the nervous tissue of oxaliplatin-treated rats and prevents
spinal oxidative alterations reducing the lipid peroxidation and
carbonylated protein levels. The maintenance of the defensive
properties of catalase, and the consequent redox balance
improvement, are concomitant with the control of pain exerted
by the PPARc agonist. A relationship between pain and catalase
impairment is suggested. Rosiglitazone reduces oxaliplatin-depen-
dent alterations of the pain threshold when both noxious or non-
noxious stimuli are used. The anti-neuropathic effect is dose- and
time-dependent till day 14. On day 21, the effect of 3 and 10 mg
kg21 is similar in the Cold plate test. On the same day, the low
dose treated animals (3 mg kg21) show an improvement in motor
coordination and a significant restoration of catalase expression
and activity in the central nervous system, whereas the beneficial
effect of the higher dose (10 mg kg21) disappears. These evidences
suggest the need of a mild PPARc stimulation to obtain a
protective antineuropathic effect. Interestingly, the 10 mg kg21
dosage prevents the increase of astrocyte number in the spinal
cord, on the contrary the lower dose is ineffective. Glia cells
contribute to the persistence of pain [68] as well as to several
omeostatic functions above all neuroprotection [69]. The block of
glial-related signals impairs functional recovery after nerve injury
[70], suggesting that tout court glial inhibition may relieve pain but
hinders the rescue mechanisms that protect nervous tissue.
Accordingly, the present data suggest that the lower dose of
rosiglitazone (which is unable to decrease astrocyte cell number)
yields the better balance between neuroprotective and anti-
hyperalgesic effects. On the other hand, the effect of rosiglitazone
on glia cells is not univocally depending by pathological condition
and by CNS area. In rats, 0.1 mg kg21 rosiglitazone (i.p.) was able
to decrease the cognitive impairment after status epilepticus and to
inhibit astrocyte activation in the striatum [71]. On the contrary,
in a rat Parkinson’s model, the neuroprotective effect induced by
Scale bar 50 mm. In the lower panel quantitative analysis of cellular density is shown. Each value represents the mean 6 S.E.M. of 10 rats per group,
performed in 2 different experimental sets. *P,0.05 vs vehicle + vehicle; ‘P,0.05 vs oxaliplatin + vehicle.
doi:10.1371/journal.pone.0102758.g007
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3 mg kg21 rosiglitazone (i.p.) is concomitant with an increase in
GFAP expression in the hippocampus [72]. Noteworthy, the
capability of rosiglitazone to penetrate the blood brain barrier is
debated [73–75], though central effects have been demonstrated
[76].
Finally, it is important to highlight the absence of interaction
between the PPAR-c agonist and the lethal effect exerted by
oxaliplatin on the human colon cancer cells HT-29. Moreover,
thiazolidinediones reduce the growth of different tumors, arresting
cancer cell proliferation by affecting cell cycle checkpoints or
inhibiting growth factors [77]. Preclinical and clinical studies have
demonstrated the antitumoral effect of rosiglitazone alone or in
combination [78].
In summary, oxaliplatin-dependent neurotoxicity alters perox-
isome functionality. The PPARc agonist rosiglitazone prevents
these phenomena and controls pain. The optimal profile shown by
the lower dosage suggests the mild stimulation of PPARc as
possible approach to the oxaliplatin neuropathy.
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